|
3rd International AIDS Society Conference on HIV Pathogenesis and TreatmentRio de Janeiro - July 24-27, 2005 |
Main TOC Monday TOC Wednesday TOC
Cite as: IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd: Abstract No. xx
where xx is the abstract number.
| Tuesday FORUM • 01 |
|
| TuFo01 Complications of HIV therapy |
|
 TuFo0101 |
CARDIOVASCULAR RISK OF HIV THERAPY IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuFo0101) Bruno Caramelli This is a Power Point presentation. There is no abstract available. |
| TuFo0102 |
IMPLICATIONS OF METABOLIC TOXICITY IN RESOURCE-LIMITED SETTINGS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuFo0102) Elly Katabira This is a Power Point presentation. There is no abstract available. |
 TuFo0103 |
RENAL EFFECTS OF HIV THERAPY IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuFo0103) Marianne Harris This is a Power Point presentation. There is no abstract available. |
| TuFo0105 | SHIFT FROM PROTEASE INHIBITOR- TOWARDS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR-BASED HAART VERSUS LIPID-LOWERING TREATMENT, FOR THE MANAGEMENT OF HAART-RELATED DYSLIPIDEMIA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuFo0105) Calza L., Manfredi R., Colangeli V., Tampellini L., Sebastiani T., Pocaterra D., Chiodo F. Pravastatin and bezafibrate proved significantly more effective in the management of HAART-related hyperlipidemia, than the switching therapy from a protease inhibitor-based regimen, toward a nevirapine- or efavirenz-based one. Further studies are needed to elaborate guidelines for pharmacological management of HAART-associated hyperlipidemia. |
| TuFo0106 | CHARACTERIZATION OF ANEMIA IN HIV-INFECTED (HIV+) SUBJECTS TREATED WITH ANTIRETROVIRAL THERAPY (ART) WITH AND WITHOUT ZIDOVUDINE (+/- ZDV) IN 54 CLINICAL TRIALS. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuFo0106) Edwards M., Burkle W., Cutrell A., Liao Q., Brothers C., Hernandez J. The overall incidence of anemia in this cohort was low (1%). Subjects treated with ZDV had a higher incidence of anemia compared to subjects not treated with ZDV. This incidence, however, was low and appeared to be lower when COM/TZV were used. |
| FORUM • 02 | |
| TuFo02 PMTCT toxicity and resistance |
|
| TuFo0202 | ADVERSE PREGNANCY OUTCOMES IN HIV INFECTED WOMEN TREATED WITH HAART IN ABIDJAN CÔTE d'IVOIRE IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuFo0202) Tonwe-Gold B., Becquet R., Kone M., Ayekoe I., Viho I., Toure P., Ekouevi D.K., Abrams E.J., Dabis F., Leroy V. We found a higher rate of low birth weight in HAART treated women compared to women not eligible for HAART treatment, but no difference in stillbirth and neonatal mortality rates. Further larger scale investigations should be performed to assess the risk of HAART on pregnant women in the context of scaling up in low-income countries. |
| TuFo0203 |
VIRAL RESISTANCE AND PMTCT ANTIRETROVIRAL REGIMENS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuFo0203) Christine Rouzioux Power Point Presentation |
| TuFo0204 | ADDITION OF SHORT COURSE COMBIVIR (CBV) TO SINGLE DOSE VIRAMUNE (SDNVP) FOR THE PREVENTION OF MOTHER TO CHILD TRANSMISSION (PMTCT) OF HIV-1 CAN SIGNIFICANTLY DECREASE THE SUBSEQUENT DEVELOPMENT OF MATERNAL AND PAEDIATRIC NNRTI-RESISTANT VIRUS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuFo0204) McIntyre J.A.1, Martinson N., Gray G.E., Hopley M., Kimura T., Robinson P., Mayers D. SdNVP+CBV can significantly decrease the subsequent development of maternal and paediatric drug resistant HIV-1. The optimal duration of CBV is uncertain and the two sdNVP+CBV arms remain open to accrual. |
| FORUM • 03 | |
| TuFo03 New challenges in HIV co-infections |
|
| TuFo0301 |
MALARIA & HIV CO-INFECTION IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuFo0301) Jimmy Whitworth Power Point Presentation. |
| TuFo0302 |
IMMUNE RECONSTITUTION DISEASE: CURRENT ISSUES IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuFo0302) Bill Powderly MD Power Point Presentation. |
| TuFo0303 |
MANAGEMENT OF THE HIV PATIENT CO-INFECTED WITH HBV/HCV WITH END STAGE LIVER DISEASE (ESLD) IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuFo0303) José M. Miró, MD, PhD Power Point Presentation. |
| TuFo0304 |
CHANGING INFLUENCE OF ART ON OPPORTUNISTIC ILLNESSES (OIS) IN THE UNITED STATES, 1994-2003 IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuFo0304) A.D. McNaghten, Debra L. Hanson, Patrick S. Sullivan Power Point Presentation. |
| FORUM • 04 | |
| TuFo04 Role of adaptive immunity and viral evolution in vaccine design |
|
| TuFo0403 |
IMMUNE SELECTION OF VIRAL VARIANTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuFo0403) Simon Mallal Power Point Presentation. |
| ORAL ABSTRACTS • 01 | |
TuOa01 HIV vaccine development trials |
|
| TuOa0101 | CONTROL OF VIREMIA AFTER ANTIRETROVIRAL TREATMENT AND THERAPEUTIC VACCINATION WITH NOVEL FORMS OF DNA VACCINES IN CHRONICALLY SIVMAC251-INFECTED MACAQUES IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuOa0101) Felber B.1, von Gegerfelt A.1, Rosati M.1, Alicea C.1, Roth P.1, Bear J.1, Valentin A.1, Boyer J.2, Weiner D.3, Bischofberger N.4, Markham P.5, Albert P.6, Franchini G.6, Pavlakis G.1 The combination of novel forms of DNA vaccines administered during ART treatment induced an immune response able to control viremia after removal of ART. Importantly, animals able to control virus maintained this ability for two years after ART termination. Optimized DNA vectors may be beneficial either alone or in combination with other vaccine modalities as an addition to antiretroviral treatment. |
| TuOa0102 | IMMUNE MODULATION IN HAART-NAÏVE, ASYMPTOMATIC HIV-INFECTED INDIVIDUALS UNDERGOING THERAPEUTIC VACCINATION WITH HIV-1 WHOLE KILLED VACCINE IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuOa0102) Gori A.1, Trabattoni D.2, Rizzardini G.3, Maserati R.4, Schenal M.2, Fasano F.2, Mazzotta F.5, Theofan G.6, Bray D.H.7, Clerici M.2 Immunotherapy with REMUNE is associated with changes in circulating lymphocytes phenotype and, possibly, with a positive effect on thymic functions. Data from larger cohorts of subjects are required to assess clinical significance of these observations. |
| TuOa0103 | CROSS CLADE CD8+ T CELL RESPONSES IN PRIMARY HIV-1 CLADE B INFECTION IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuOa0103) Malhotra U.1, Nolin J.1, Maenza J.1, McElrath M.J.1 Extensive cross-clade T-cell responses exist in primary HIV-1 infection. Surprisingly, responses to both clade-specific and cross-clade peptides were detected with similar sensitivity, despite significantly smaller amino-acid diversity between isolate and clade-specific consensus-sequences compared to cross-clade sequences (3-8% vs. 15-30%). Finally, we conclude that new strategies to augment T-cell epitope coverage provided by consensus sequences, specifically in domains with moderate and high sequence variability, are needed. |
| TuOa0104 | HOST GENETICS, VIRAL SEQUENCE DIVERSITY AND ANTIVIRAL CELLULAR AND HUMORAL IMMUNITY IN HIV-1 CLADE B INFECTED INDIVIDUALS IN PERU IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuOa0104) Zuniga R.1, Lucchetti A.1, Galvan P.1, Sanchez S.1, Peinado J.1, Frahm N.2, Linde C.2, Hewitt H.2, Hildebrand W.H.3, Montefiori D.4, Allen T.2, Altfeld M.2, Walker B.D.2, Sanchez J.1, Brander C.2 Together, this is the first study to combine a detailed assessment of nAb, CTL and Th-cell responses, viral sequence analysis and host genetics to guide HVI vaccine design and highlight the importance of defining these factors for the design of potential vaccine candidates. |
| TuOa0105 | AN EXTREMELY COMMON MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I ALLELE IN MAURITIAN CYNOMOLGUS MACAQUES IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuOa0105) Krebs K., Rudersdorf R., Jin Z., OConnor D. These studies will lay the foundation for the use of Mauritian Cynomolgus macaques in AIDS vaccine studies that elicit CD8+ T cell responses. The HIV and SIV research communities stand to benefit considerably from the availability and reduced genetic diversity of Mauritian Cynomolgus macaques. |
| TuOa0107 | ASSESSING POTENTIAL CANDIDATES FOR HIV PREVENTION TRIALS IN A VERY POOR AREA OF RIO DE JANEIRO STATE, BRAZIL IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuOa0107) Velasco de Castro C.1, Grinsztejn B.2, Veloso V.G.2, Bastos F.I.3, Pilotto J.H.4, Paiva M.2, Friedman R.2, Moreira R.I.2, Morgado M.G.5 The high rate of incident infections we found indicates the vulnerability of poor population to HIV/AIDS. It also shows the usefulness of this assay to identify recent HIV infections. In Rio de Janeiro, VCTs attended by very poor population can be an adequate setting for recruitment of potential candidates to HIV prevention and therapeutic trials targeting recently infected individuals. |
| ORAL ABSTRACTS • 02 | |
| TuOa02 New antiretroviral agents |
|
| TuOa0201 | SMALL MOLECULE HIV ENTRY INHIBITORS TARGETING GP41 IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuOa0201) Jiang S., Lu H., Liu S., Zhao Q., He Y., Debnath A.K. These potent small molecule anti-HIV-1 compounds may interact with the components in the gp41 heptad repeat regions and block formation of the fusogenic core of six-helix bundle, thereby inhibiting gp41-mediated membrane fusion. These compounds will be used as leads for development of novel anti-HIV drugs, small molecule HIV entry inhibitors targeting gp41. |
| TuOa0202 | IMMUNE THERAPY OF ADVANCED HIV-1 INFECTION BY TRANSDUCED AUTOLOGOUS T HELPER CELLS EXPRESSING A PEPTIDE WHICH INHIBITS VIRAL ENTRY. RESULTS OF A PHASE I PILOT STUDY IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuOa0202) van Lunzen J.1, Glaunsinger T.1, Stahmer I.1, Kühlcke K.2, Schilz A.2, Stellbrink H.J.1, Mayr C.3, Dinauer N.4, Alexandrov A.4, von Laer D.5 This first gene therapeutic approach for HIV infection based on entry inhibition shows promising results. Transduced CD4+ T cells have been transfused safely leading to an increase of circulating CD4+ T cells. This increase in app. 60% of these advanced patients warrant further trials in less immunocompromised cohorts. |
| TuOa0203 | TREATMENT WITH GROWTH HORMONE LEADS TO IMPROVEMENT IN TOTAL AND NAÏVE CD4 LYMPHOCYTE RECOVERY IN HIV-INFECTED SUBJECTS WITH INCOMPLETE IMMUNE RECONSTITUTION ON HAART IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuOa0203) Smith K.1, Wang R.2, Bosch R.2, Margolis D.3, Tenorio A.1, Pollard R.4, Stocker V.5, Gross B.6, Frances I.6, Muurahainen N.7, ACTG 5174 Protocol Team A.5 Treatment with rGH is associated with significant increases in total and naïve CD4 count compared to HAART alone. Treatment with rGH is associated with an increase in thymus size. This is the first randomized clinical trial to demonstrate immunologic effects of rGH combined with HAART. |
| TuOa0204 | OVERVIEW OF PHASE 1 AND 2A SAFETY AND EFFICACY DATA OF MARAVIROC (UK-427,857) IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuOa0204) McHale M., Abel S., Russell D., Gallagher J., van der Ryst E. The development program to date has demonstrated that maraviroc is well tolerated at doses up to and including 300mg BID and that 10 day monotherapy resulted in significant reductions in viral load. These results indicate that further evaluation of maraviroc for the treatment of HIV infection is merited. |
| TuOa0205 | SCH 417690: ANTIVIRAL ACTIVITY OF A POTENT NEW CCR5 RECEPTOR ANTAGONIST IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuOa0205) Schuermann D.1, Pechardscheck C.1, Rouzier R.2, Nougarede R.2, Faetkenheuer G.3, Ochlast I.3, Raffi F.4, Hoffman C.5, Greaves W.6, Sansone A.6 SCH 417690 demonstrated potent antiviral activity against CCR5-using HIV-1 strains at all doses studied. These findings, along with the marked post-antiviral effect which lasted a number of days after completion of dosing, support further clinical development of SCH 417690. |
| TuOa0206 | ANTIVIRAL SYNERGY BETWEEN THE CCR5 MAB PRO 140 AND SMALL-MOLECULE CCR5 ANTAGONISTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuOa0206) Murga J., Olson W., Pevear D. PRO 140 inhibits HIV-1 entry synergistically with small-molecule CCR5 antagonists and with T-20. The findings support the use of PRO 140 in combination with other HIV-1 entry inhibitors and suggest that PRO 140 represents a distinct CCR5 inhibitor subclass. |
| ORAL ABSTRACTS • 03 | |
| TuOa03 Prevention of mother-to-child transmission worldwide |
|
| TuOa0301 | HIV-INFECTED PREGNANT WOMEN AND MOTHER-TO-CHILD TRANSMISSION IN EUROPE: CHARACTERISTICS OF THE EPIDEMICS IN WESTERN, CENTRAL AND EASTERN EUROPE IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuOa0301) Thorne C.1, Patel D.1, Malyuta R.2, Semenenko I.2, Newell M.-L.1, European Collaborative Study T.1 There is substantial sub-regional variation in the HIV epidemic among pregnant women across Europe. MTCT rates in Western/Central Europe are now extremely low, while in Eastern Europe, rates are somewhat higher due to the use of less effective MTCT prophylaxis and fewer elective CS deliveries. |
| TuOa0302 | CAN WE SCALE UP NATIONAL PREVENTION OF MOTHER-TO-CHILD TRANSMISSION (PMTCT) PROGRAM IN LOW RESOURCES SETTINGS ?: LESSONS LEARNED AND CHALLENGES FROM CAMEROON'S EXPERIENCE IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuOa0302) Tsague L.1, Njom Nlend A.2, Zoung-Kanyi Bissek A.1, Tchendjou P.3, Tejiokem M.3, Tih P.4, Tene G.5, Eteki N.6, Tonye R.6, Same Ekobo C.7, Engozo'o A.1, Nokouni M.1, Koulla S.8, Penda I.9, Tchendje T.10, Bella A.1 The PMTCT program has effectively embarked into the scaling up phase, but some challenges remain: consolidate the existing activities and scaling up the interventions at the district level using the "district approach", Improve into the community awareness and commitment for PMTCT. |
| TuOa0303 | FACTORS INFLUENCING THE ACCEPTANCE OF HIV VOLUNTARY COUNSELLING AND TESTING AMONG PREGNANT WOMEN IN CAMEROON'S PMTCT PROGRAM. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuOa0303) Tsague L.1, Njom Nlend A.2, Zoung-Kanyi A.C.1, Engozo'o A.1, Nokouni M.1, Tene G.3, Eteki N.4, Penda I.5, Same Ekobo C.6, Tejioken M.7, Tchendjou P.7, Tih P.8, Bella Hiag A.1 The number of trained counsellors seems to influence HIVTU in our program more than the cost of HIV testing which is only correlated. Emphasis should be made on increasing the number of well trained cousellors at PMTCT sites to ensure a quality comprehensive PMTCT package and increase the number of pregnant women accepting HIV testing. |
| TuOa0304 | ACCEPTABILITY OF ROUTINE HIV TESTING IN ANTENATAL SERVICES IN ZIMBABWE IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuOa0304) Perez F.1, Zvandaziva C.2, Engelsmann B.3, Marchand D.1, Dabis F.1 Introduction of routine HIV testing in antenatal care is acceptable to most women and would increase uptake of PMTCT services. In Zimbabwe, where 25% of pregnant women are HIV infected, introduction of these strategies would have a far reaching public health impact. Issues regarding, stigma, quality of post-testing counselling and staffing will need to be considered. |
| TuOa0305 | DISCORDANT COUPLES AMONG HIV POSITIVE PREGNANT WOMEN IN PMTCT PROGRAM IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuOa0305) Vijayakumari J.1, Rukmani R.1, Anuradha G.2, Jacob M.1, Srijeyanth P.1, Samuel N.M.1 HIV discordant couples where the husbands are negative exist in the rural Indian population. In spite of discordance, the couples live together. Repeated couple counseling is essential for providing psychosocial support and for preventing seroconversion. |
| TuOa0306 | TREATMENT OUTCOMES OF NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI)-BASED COMBINATION THERAPY IN THAI MTCT-PLUS PATIENTS FOLLOWED UP WITH LOW-COST TOOL: RESULTS AT 12 MONTHS. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuOa0306) Phanuphak N., Apornpong T., Teeratakulpisarn S., Phanuphak P. MTCT-Plus model of care in the setting of developing country, using strong adherence support provided by highly effective teamwork and low-cost follow-up tool, provides very high adherence rate among patients receiving NNRTI-based combination therapy along with significant improvement in CD4 counts over 12 months. |
| ORAL ABSTRACTS • 04 | |
| TuOa04 Sexual transmission |
|
| TuOa0401 | FEMALE CIRCUMCISION AND HIV INFECTION IN TANZANIA: FOR BETTER OR FOR WORSE? IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuOa0401) Stallings R.Y.1, Karugendo E.2 A lowered risk of HIV infection among circumcised women was not attributable to confounding with another risk factor in these data. Anthropological insights on female circumcision as practiced in Tanzania may shed light on this conundrum. |
| TuOa0402 | IMPACT OF MALE CIRCUMCISION ON THE FEMALE-TO-MALE TRANSMISSION OF HIV IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuOa0402) Auvert B.1, Puren A.2, Taljaard D.3, Lagarde E.4, Sitta R.4, Tambekou J.4 Male circumcision provides a high degree of protection against HIV infection acquisition. Male circumcision is equivalent to a vaccine with a 63% efficacy. The promotion of male circumcision in uncircumcised males will reduce HIV incidence among men and indirectly will protect females and children from HIV infection. Male circumcision must be recognized as an important means to fight the spread of HIV infection and the international community must mobilize to promote it. |
| TuOa0403 | HUMAN PAPILLOMAVIRUS IS ASSOCIATED WITH HIV ACQUISITION: THE EXPLORE STUDY IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuOa0403) Chin-Hong P.1, Husnik M.2, Benet D.3, Buchbinder S.4, Colfax G.4, Cranston R.5, Da Costa M.1, Darragh T.1, Judson F.6, Koblin B.7, Mayer K.8, Vittinghoff E.1, Palefsky J.1 Anal HPV and ASC on anal cytology are independently associated with HIV acquisition. Prospective studies that incorporate high-resolution anoscopy for more sensitive visual and histologic identification of AIN are needed to extend these cytologic findings. Identification of HPV and HPV-associated lesions may improve assessment of HIV transmission risk. |
| TuOa0404 | EXPLORING SEXUAL BEHAVIOR OF PEOPLE LIVING WITH HIV PRIOR TO HAART: EXPERIENCES FROM THAILAND IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuOa0404) Oberdorfer A.1, Chariyalertsak S.2, Thapinta D.3, Suwantherangoon J.1, Guest P.4, Wu A.5, Sarna A.6 Consistent condom use was lower among some specific participants especially those who did not know about the HIV status of their partners as well as those couples who both were HIV positive. Disclosure and consistent condom use should be encouraged among these groups. |
| TuOa0405 | WOMEN SURVIVAL SEX WORKERS IN VANCOUVER'S DOWNTOWN EASTSIDE: A HIDDEN HIV EPIDEMIC IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuOa0405) Shannon K.1, Bright V.2, Duddy J.3, Oleson M.1, Gibson K.4, Tyndall M.W.5 HIV infection among survival sex workers in Vancouver is associated with risky drug use patterns, inconsistent condom use, and early age of initiation into sex work. Given the high levels of mobility along with inconsistent condom use, there is a growing potential for HIV transmission to clients in other parts of the city. With 26% of women already HIV positive, there is an urgent need to expand HIV prevention and care strategies that address the multiple risks faced by these women as well as the serious public health consequences of continued neglect. |
| TuOa0406 | THE FIRST SEXUAL EXPERIENCE OF UNMARRIED MALES IN IBADAN,NIGERIA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuOa0406) Adewole D.A.1, Lawoyin T.O.2 Family life education should be given before the age of 17 years and certainly before university education when most would have been sexually experienced. Adolescents and youths need to be given skills to resist unplanned SI as condoms are less likely to be used. |
| POSTER PRESENTATION • 01 | |
| TuPp01 HIV-specific cellular immunity |
|
| TuPp0101 | HIGH DEGREE OF INTER-CLADE CROSS-REACTIVITY OF HIV-1-SPECIFIC T CELL RESPONSES ON THE SINGLE PEPTIDE LEVEL IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPp0101) Yu X., Lichterfeld M., Perkins B., Chen J., Cheng M., Kang W., Brander C., Walker B., Altfeld M. Viral epitopes within regions of low HIV-1 clade B diversity and high inter-clade homology can be recognized in the clade A, B and C variants and indicate a wide degree of cross-isolate and cross-clade recognition by HIV-1-specific T cells. These regions may therefore be of particular relevance for the design of HIV-1 vaccines. |
| TuPp0102 | IMMUNODOMINANCE AND CROSS-RECOGNITION OF CD8+ T CELL REPONSES IN HIV-1-INFECTED CHINESE IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPp0102) Kang W.1, Yu X.G.2, Zhai S.1, Zhuang Y.1, Wang S.1, Li X.1, Altfeld M.2, Wu X.1, Perkins B.A.2, Walker B.D.2, Sun Y.1 These studies indicate that the HIV-1-specific T cell responses cluster in Gag and Nef proteins, which is in line with previous studies in infected Caucasians and other ethnics. There are cross-recognition of CD8+ T cell responses between HIV-1 clade B and C. More detailed studies are needed to investigate the impact of HLA genetic background and infecting clades on the cellular responses in infected Chinese, however, it is promising to be able to design a vaccine covering the different strains circulating in China. |
| TuPp0103 | DURATION OF HIV EXPOSURE MODULATES THE BREADTH AND THE MAGNITUDE OF HIV-SPECIFIC MEMORY CD4+ T CELLS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPp0103) Younes S.-A.1, Trautmann L.2, Diab B.Y.2, Dumont A.2, Kalfayan L.2, Kernaleguen A.-E.2, Lainesse M.2, Boulassel R.3, Routy J.-P.3, Sékaly R.-P.2 Our data indicate that a short or prolonged exposure to high levels of HIV leads to diminishing HIV-specific CD4+ T cell responses. A better understanding of HIV-specific CD4+ T cell responses in early HAART treated patients could contribute to the design of a vaccine against HIV to restaure a memory compartment efficient and stable in time. |
| TuPp0104 | THE LYSISPOT ASSAY REVEALS HIV-SPECIFIC T CELLS CAN LYSE TARGETS WITHOUT SECRETING IFN-γ DIRECTLY EX VIVO, AND THE RELATIVE FREQUENCIES OF IFN-γ SECRETING AND CYTOTOXIC CELLS VARY BOTH AMONGST HIV-SPECIFIC AND IN COMPARISON TO CMV, EBV RESPONSES WITHIN INDIVIDUAL PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no.TuPp0104) Snyder-Cappione J.E., Divekar A.A., Maupin G.M., Jin X., Demeter L.M., Mosmann T.R. The IFN-γ and cytotoxic effector functions are independently exerted by individual HIV-specific T cells directly ex vivo from chronically infected subjects. Also, comparisons of these two effector functions between HIV-specific T cells and T cells specific for other chronic infections within individual subjects indicate the HIV-specific T cells are not 'pre-terminally differentiated' as previously suggested. Further analysis of the frequencies of directly cytotoxic T cells may be of considerable value in the assessment of disease progression and the efficacy of HIV vaccines. |
| TuPp0105 | EVALUATION OF VIRAL-SPECIFIC CD8 T CELL RESPONSES IN HIV-1+ PATIENTS WITH DIFFERENT EFFECT OF LONG-TERM HAART IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPp0105) Magaev S.1, Nikolova M.1, Kostov K.2, Beshkov D.1, Varleva T.3, Taskov H.1 A good response to HAART results in viral load suppression and promotes the functional differentiation of CTL (group A). In contrast, persisting viral replication results in accumulation of intermediately differentiated effectors (group C). The combination of CD4 depletion and viral overload (group B) ends with the exhaustion of the CD8 T cell functional pool and the accumulation of activation-resistant senile cells. |
| TuPp0106 | ROLE OF THE THYMUS IN HIV PATHOGENESIS AND IN IMMUNE RECONSTITUTION IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPp0106) Grossman Z.1, Dion M.-L.2, Alon H.1, Routy J.-P.3, Sekaly R.-P.4, Cheynier R.5 Suppression of thymic production by HIV may contribute to disease progression, contrary to what has recently been suggested by others. Under HAART, the thymus probably contributes to immune reconstitution both numerically and by providing clones with a diverse repertoire. |
| POSTER PRESENTATION • 02 | |
| TuPp02 Strategies to increase VCT uptake |
|
| TuPp0201 | TAKING IT TO THE STREETS: MOBILE UNITS FOR COUPLES VOLUNTARY COUNSELING AND TESTING IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPp0201) Casanova D.1, Rwanda Zambia HIV Research Group Z.E.H.R.P.2 Successful MU sites depend on the participation of community and political/administrative leaders as well as the type of site. In Kigali, the most successful MU benefited from strong INL involvement and additional leaders at the grassroots level. In Lusaka, bringing services closer to the community through MUs has not been successful. Additional political/administrative and grassroots leaders have not been fully utilized in promoting MUs and these sites may not be far enough away from the fixed site. |
| TuPp0202 | WHAT INFLUENCES COUPLES TO GET TESTED AT COUPLES VCT CENTERS IN KIGALI, RWANDA AND LUSAKA, ZAMBIA. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPp0202) Sardar G.1, Rwanda Zambia HIV Research Group Z.2 The same promotional activities yielded very different results in the two cities. One-on-one contact with an INA is an effective means of promoting CVCT in both Kigali and Lusaka. The hoped for 'snowball effect' only occurred in Kigali, with tested couples referring many friends for CVCT. Radio was also a more effective strategy in Kigali, where there is only one local language. In Lusaka, 5 major language groups and 72 dialects are represented in a large number of radio stations. |
| TuPp0203 | UNDERSTANDING MALE AND FEMALE EXPERIENCE AND NEEDS IN RELATION TO HIV TESTING IN RURAL ZIMBABWE IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPp0203) SHerr L.1, Gregson S.2, Nyamukapa C.3, Oberzaucher N.4, Lopman B.5, Mushati P.3, Garnett G.5, Chandiwana S.3 This data has implications for strategy, the quality of provision of VCT and a reappraisal of stereotypes in the literature – especially in relation to men. |
| TuPp0204 | HIGH UPTAKE OF VOLUNTARY COUNSELLING AND TESTING (VCT) SERVICES USING THE MOBILE AND HOME-TO-HOME (M&H-H) APPROACHES IN 2 TWO DISTRICTS IN EASTERN UGANDA, THROUGH THE AIDS INFORMATION CENTRE (AIC) IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPp0204) Murana E., Okello B.N. Partnerships with local stakeholders and agencies providing care and support services are crucial for sustainability of this service. Capacity building for CORPs is vital. |
| TuPp0205 | CREATING DEMAND FOR VCT: A MULTI-COUNTRY EXAMINATION OF SOCIAL MARKETING PROGRAMS FOR VCT IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPp0205) Joseph D., Richter K., England S. Social marketing of VCT using mass media and IPC focusing on the positive benefits and importance of VCT are an effective means of promoting VCT and decreasing stigma around HIV-testing. However, more analysis is needed to assess the best way to promote and deliver cost-effective VCT to high-risk groups in lower-prevalence settings. |
| TuPp0206 | COMPLIMENTARITY OF VOLUNTARY COUNSELING AND TESTING (VCT) SERVICES AND HIV CARE AND TREATMENT PROGRAMS IN TANZANIA. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPp0206) Mduma B., Dulle R., Temu F., Didi A., Ocheng D., Gavyole A. Rapid HIV testing is now acceptable countrywide, and feasible to many people. This has increased the number of people accessing VCT services and consequently referred to among others, care and treatment services. |
| POSTER PRESENTATION • 03 | |
| TuPp03 HIV drug resistance around the world |
|
| TuPp0301 | PATTERNS OF HIV-1 GENOTYPIC ANTIRETROVIRAL RESISTANCE IN CLINICAL PRACTICE: A SURVEY OF THE BRAZILIAN NETWORK FOR GENOTYPIC RESISTANCE IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPp0301) Munerato P.1, Andreo S.M.1, Sucupira M.C.1, Mamede S.2, Mota G.1, Sá Filho D.1, Cavalieri E.1, Arakaki D.2, Marins J.R.P.2, Diaz R.S.1 We found high prevalence of TAM. Almost half of patients failing Nelfinavir had limited chances of salvage by other PI. Resistance to Nelfinavir in non-B strains most frequently related to other mutations than 30N or 90M. The genotypic patterns of resistance between clades B and F are distinct in protease, revealing a poor understanding of resistance correlates in F strains. |
| TuPp0302 | HIV-1 DRUG RESISTANCE IN CHINA: NATION-WIDE SURVEY AND ANALYSIS OF IMPACTING FACTORS IN THE NATIONAL ARV TREATMENT PROGRAM IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPp0302) Xing H.1, Jiang S.1, Si X.1, Cheng H.1, Shang H.2, Li J.3, Kang L.4, Zhong P.44, Shao Y.1 The frequency of HIV DR-related mutation is very low in drug naïve HIV-1 infected subjects in China. The regimens of AZT/3TC/NVP and D4T/DDI/EFV are better than AZT/DDI/NVP and D4T/DDI/NVP measured by viral control and inhibition of HIV DR-related mutations. The emergence of DR-related mutation was the cause of ART treatment failure. |
| TuPp0303 | THE PRESENCE OF A SINGLE CANONICAL NNRTI RESISTANCE MUTATION IN NAÏVE HIV-1 INFECTED PATIENTS REDUCES THE PROPORTION ACHIEVING VIROLOGICAL SUCCESS WHEN STARTING NNRTI-BASED REGIMENS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPp0303) Price H., Jones R., Mandalia S., Bower M., Nelson M., Gazzard B. More than half the patients treated with NNRTI regimens responded despite pre-existing resistance although response to a PI containing regimen was better. |
| TuPp0304 | HIV-PROVIRAL DNA AND PLASMA-RNA SEQUENCING FOR DETECTION OF DRUG RESISTANCE MUTATIONS IN ANTIRETROVIRAL NAÏVE PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPp0304) Parisi S.G.1, Mazzi R.2, Zazzi M.3, Manfrin V.4, Nicolini G.5, Carolo G.6, Boldrin C.1, Franchin E.1, Dal Bello F.1, Gatti F.2, Palù G.1 We found drug resistance in 21 out of 60 naïve-pts (35%), but only in 6 Copts and 9 Dipts (25%) this resistance was at least partially evident with conventional PL-analysis. A substantially different virus was found in PBMCs of 10 Dipts, revealing a dual infection, a recent superinfection or a reversion of an originally infecting resistant virus, with the storage of the less fit variant, still detectable as transient prevalent population in the PBMC-archive. We suggest that PBMCs analysis is useful in naïve pts to detect stored resistant variants that may compromise future therapy options. |
| TuPp0305 | LACK OF RESISTANCE TO TENOFOVIR AT WEEK 48 AND IMPACT OF BASELINE RESISTANCE MUTATIONS ON TREATMENT RESPONSE IN STUDY 934 IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPp0305) McColl D., Margot N., Lu B., Cheng A., Miller M. Resistance development occurred less frequently in the TDF/FTC arm of study 934 compared to the CBV arm (3.7% versus 7%, mITT). Fewer pts on TDF/FTC developed M184V and no pt developed K65R through 48 weeks. A significantly greater proportion of pts with BL NNRTI-R met RA criteria and then developed further NNRTI-R and/or M184V. The effectiveness in ART-naïve HIV patients of combination regimens including an NNRTI would be improved by the use of genotyping prior to starting therapy. |
| TuPp0306 | HIGH RATE OF VIROLOGICAL FAILURE DURING ONCE DAILY THERAPY WITH TENOFOVIR + DIDANOSINE 250MG + EFAVIRENZ IN ANTIRETROVIRAL NAÏVE PATIENTS – RESULTS OF THE 12 WEEK INTERIM ANALYSIS OF THE TEDDI TRIAL IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPp0306) van Lunzen J.1, Schewe K.2, Kuhlmann B.3, Hoffmann C.4, Stoll M.5, Dellamonica P.6, Prazuck T.7, Benech H.8, Taburet A.M.9, Delfraissy J.F.9 OD TDF/ddI/EFV was safe and led to a strong CD4 cell recovery. However, an unexpected high rate of virological failure was observed in patients with high BL viral loads and low CD4 counts. Thus this regimen should not be recommended in these patients. |
| POSTER PRESENTATION • 04 TuPp04 - |
|
| TuPp04 Understanding prevention of mother-to-child transmission |
|
| TuPp0401 | PREGNANCY OUTCOMES IN HIV-INFECTED AND UNINFECTED WOMEN IN URBAN AND RURAL SOUTH AFRICA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPp0401) Rollins N.1, Coovadia H.2, van den Broeck J.3, Bland R.3, Bennish M.3, Newell M.L.4, for the Vertical Transmission Study 3 Maternal HIV infection is associated with an increased risk of miscarriages, stillbirths but not neonatal mortality. HIV-exposed infants were lighter and more likely of low birth weight. Optimising antenatal care of HIV-infected women including appropriate antiretroviral drugs may reduce early fetal losses and improve birthweight in their offspring. |
| TuPp0402 | NEVIRAPINE CONCENTRATION IN CERVICO-VAGINAL AND OROPHARYNGEAL SECRETIONS IN A MOTHER-CHILD COHORT IN UGANDA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPp0402) Kunz A.1, Karcher H.1, Mayer A.1, Simo S.1, Mugenyi K.2, Kurowski M.3, Stocker H.3, Mashate S.2, Harms G.1 Cervico-vaginal and oropharyngeal secretions contained high concentrations of nevirapine after single dose application to the mother. Nevirapine levels in these body compartments may contribute to the protective effect of the drug towards HIV mother to child transmission. |
| TuPp0403 | HIV DRUG RESISTANCE AMONG WOMEN USING PROPHYLACTIC ANTIRETROVIRALS DURING PREGNANCY: A POST-PARTUM ANALYSIS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPp0403) Kakehasi F., Aleixo A., Cleto S., Lin E., Melo V.H., Peret F., Romanelli R., Teatinni M.d.C., Pinto J. In this group of women the exposure to ARTs during pregnancy was very efficient to block MTCT with a low level of drug resistance mutation. The finding of low ART resistance rates is probably associated with the low viral load achieved observed in these women. |
| TuPp0404 | ROUTINE USE OF COMBINED ZIDOVUDINE AND NEVIRAPINE REGIMEN IN MTCT-PLUS PROGRAM IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPp0404) Marcy O.1, Mafoua A.2, Halembokaka G.2, Tran-Minh T.1, Courpotin C.1, Lingouala G.3, Adam G.1, Mattei J.-F.1 In routine MTCT program, combined ZDV NVP regimen proves to be feasible and effective in reducing MTCT but efficacy is impaired by low adherence to one of the stages. Adherence support through counseling and education should be emphasized even when using short course MTCT regimen. |
| TuPp0405 | TIMING OF MATERNAL AND INFANT NEVIRAPINE AND THE RISK OF MOTHER-TO-CHILD TRANSMISSION OF HIV-1: HIVNET 024 IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPp0405) Chi B.H.1, Wang L.2, Read J.S.3, Sheriff M.4, Fiscus S.5, Brown E.6, Valentine M.7, Adeniyi-Jones S.8, Goldenberg R.L.9 Variations in the timing of maternal and infant NVP doses (within reasonable proximity to delivery) do not appear to affect the risk of MTCT. |
| TuPp0406 | THE EFFICACY AND SAFETY OF CESAREAN DELIVERY FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV-1: A SYSTEMATIC REVIEW (COCHRANE COLLABORATION) IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPp0406) Read J.1, Newell M.-L.2 ECS is an efficacious intervention for the prevention of MTCT. The risk of PPM with ECS is higher than that associated with vaginal delivery, yet lower than with NECS. Among HIV-1-infected women, more advanced maternal HIV-1 disease stage and concomitant medical conditions (e.g., diabetes) are independent risk factors for PPM. |
| POSTER EXHIBIT | |
| TuPe1.1C Hepatitis viruses |
|
| TuPe1.1C01 | EFFICACY OF ACUTE HCV TREATMENT WITH PEG-INTERFERON α-2B AND RIBAVIRIN IN HIV INFECTED PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.1C01) Kruk A. After 24 weeks of acute HCV treatment with peg-interferon alfa-2b and ribavirin 15 (88%) of treated patients were HCV RNA negative. Peg-interferon and ribavirin show good antiviral efficacy in HIV/HCV co-infected patients. Discontinuation rate is low, but depression is a major problem in this cohort with a high proportion of drug users. |
| TuPe1.1C02 | SOCIAL CORRELATES OF CO-INFECTION WITH HIV AND HEPATITIS C IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.1C02) Grierson J.1, Pitts M.1, Thorpe R.1, O'Brien M.2 While many aspects of living with HIV are shared regardless of hepatitis C status, some issues are likely to affect co-infected PLWHA more than their peers. This has important implications for responses by community organisations (both HIV specific and hepatitis specific) and for those involved in clinical and health management. |
| TuPe1.1C03 | SAFETY OF A FOSAMPRENAVIR/RITONAVIR (FPV/R) CONTAINING REGIMEN OVER 120 WEEKS IN HIV-1 INFECTED THERAPY-NAÏVE ADULTS WITH OR WITHOUT HEPATITIS B (HBV) AND/OR C (HCV) CO-INFECTION IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.1C03) DeJesus E.1, Gladysz A.2, Vera J.3, Pulido F.4, Carosi G.5, Garris C.6, Givens N.7, Yeo J.7, Felton M.7 • Subjects in both the co-infected and non co-infected groups who completed at least 120 weeks had a median decrease in ALT and AST. • Incidence of AEs was comparable between co-infected subjects and those without co-infection. • In co-infected subjects, minimal additional liver toxicity was observed with longer term FPV/r QD therapy. |
| TuPe1.1C04 | THE PREVALENCE AND SIGNIFICANCE OF GBV-C VIRUS INFECTION IN HIV-INFECTED KENYAN MOTHERS AND THEIR INFANTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.1C04) Low A., Essajee S. Contrary to a recent study in Tanzania, this demonstrates a trend towards a decrease in vertical transmission of HIV in GBV-C co-infected mothers in Kenya. A larger cohort is currently being studied to see if this phenomenon is duplicated. In addition, this group will be followed for a four year period to investigate the outcome of GBV-C/HIV co-infection over time. |
| TuPe1.1C05 | EFFECT OF HEPATITIS C INFECTION ON IMMUNOLOGIC AND VIROLOGIC RESPONSE AMONG PERSONS WITH HIV INFECTION INITIATING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.1C05) Sullivan P.1, Hanson D.1, Teshale E.1, Wotring L.2 In our cohort, prevalent HCV infection was not associated with attenuated virologic or immunologic response after HAART initiation, except among persons with previously diagnosed alcoholism. Although HCV infection may adversely impact progression of HIV disease, it does not appear to lessen response to HAART in the first year after initiation. Understanding durability of VL suppression and long term trends in CD4 for those with HCV is important. |
| TuPe1.1C06 | IMPACT OF LAMIVUDINE (3TC) ON THE RISK OF LIVER RELATED DEATH (LRD) IN 2,041 HBSAG AND HIV-POSITIVE INDIVIDUALS. RESULTS OF AN INTERCOHORT ANALYSIS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.1C06) Puoti M.1, Cozzi-Lepri A.2, Paraninfo G.3, Lundgren J.4, Rickenbach M.5, Suarez-Lozano I.6, Winnock M.7, Gervais A.8, Gill J.9, Rockstroh J.10, Mussini C.11, Castagna A.12, De Luca A.13, d'Arminio Monforte A.14 The use of 3TC was associated with a reduced risk of LRD over a median of 4 yrs. Data need to be re-assessed after longer follow-up to verify if this effect is retained in spite of the development of YMDD mutations. |
| TuPe1.1C07 | IS FIRST LINE COMBINATION THERAPY OF CHRONIC HEPATITIS B WITH TENOFOVIR PLUS LAMIVUDINE SUPERIOR TO SEQUENTIAL THERAPY WITH TENOFOVIR AFTER RESISTANCE TO LAMIVUDINE IN HBV/HIV-COINFECTION? IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.1C07) Mauss S.1, Nelson M.2, Lutz T.3, Sheldon J.4, Bruno R.5, van Boemmel F.6, Rockstroh J.7, Stoehr A.8, Soriano V.4, Berger F.1, Berg T.6, Carlebach A.3, Schwarze-Zander C.7, Wunsche T.6, Schmutz G.1 In this cohort of HBV/HIV-coinfected individuals, strong HBV-DNA suppression was achieved in the majority of patients independent of treatment allocation. In addition HBe- and HBs-antigen loss was not different in both arms. TDF after the occurrence of 3TC-resistance was as effective as 3TC+TDF in coinfected patients with highly replicative HBV-infection. Longer follow-up will be needed to compare the durability of the viral suppression in both arms. |
| TuPe1.1C08 | CLINICAL CHARACTERISTICS AND OUTCOME OF DECOMPENSATED LIVER CIRRHOSIS IN HIV-INFECTED PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.1C08) Euba G., Shaw E., Castellote J.1, Xiol X., Podzamczer D., Santin M. Decompensated liver cirrhosis implies a poor prognosis in HIV-infected pts. In the HAART era, mortality of HIV-cirrhotic pts is mostly related to liver disease. Due to the short survival after decompensation occurs, liver transplantation should be considered as soon as possible in these pts. |
| TuPe1.1C09 | HEPATITIS C INFECTION IS NOT ASSOCIATED WITH SYSTEMIC HIV-ASSOCIATED NON-HODGKIN'S LYMPHOMA: A COHORT STUDY IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.1C09) Waters L., Stebbing J., Mandalia S., Young A.-M., Nelson M., Gazzard B., Bower M. In this immunocompromised patient population, there was no association between HCV infection and an increased risk of lymphoma. |
| TuPe1.1C10 | IS THE TREATMENT OF ACUTE HEPATITIS C IN HIV POSITIVE INDIVIDUALS EFFECTIVE? IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.1C10) Nelson M., Gilleece Y., Browne R., Asboe D., Atkins M., Mandalia S., Bower M., Gazzard B. SVR rates in HIV positive patients treated acutely for hepatitis C are lower than in HIV negative subjects. A high percentage of individuals seroconvert spontaneously. |
| TuPe1.1C11 | THE CORRELATION BETWEEN HCV AND HELICOBACTER PYLORI INFECTION AMONG HIV POSITIVE AND HIV NEGATIVE PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.1C11) Kowalska J.D., Podlasin R.B. The statistically proven correlations, between HCV and HpI among HIV+ and HIV(-) patients, were of weak strength. That is why no conclusions of clinical outcome should be made on this basis. As there are no other data about HpI prevalence in HIV/HCV co-infected patients it seems that we need more studies in this area. Frequent use of proton pomp inhibitors among patients with GI disorders may lead to serious drug-to-drug interactions, especially with ARV therapy. Thus evaluating the HpI status, among the high risk group of HCVAb(+) patients, by routine check-up of symptomatic ones and consequent eradication of H.pylori should be considered. |
| TuPe1.1C12 | PREVALENCE OF HIV, HEPATITIS B AND C VIRUSES IN HIGH RISK POPULATION IN ST. PETERSBURG, RUSSIA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.1C12) Lioznov D., Nikolaenko S., Sabadash N., Antonova T., Belayeva T. These data indicate that hepatitis C is the most frequent pathogen in this high-risk population. High prevalence of coinfection among subjects and there social status impede access to lifesaving treatment and/or limit its effectiveness. There is need in effective prevention and care programs for this population. |
| TuPe1.1C13 | THE DIFFICULTIES OF INVESTIGATING THE ROLE OF HCV COINFECTION ON SURVIVAL AND RESPONSE TO HAART IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.1C13) Bhaskaran K. We found no evidence of an independent effect of HCV on time to viral load suppression. However, it is possible that HCV-positive status contributes to the longer time to viral suppression in IDUs. It is difficult to separate these effects, given the high prevalence of HCV in IDUs. Natural history studies must tackle the problem that those tested for HCV in the pre-HAART era may be an extremely selected group with better prognosis. |
| TuPe1.1C14 | LIVER ENZYME ELEVATION AFTER SINGE PI VS. BOOSTED PI VS. NNRTI-BASED HAART IN A COHORT OF 1038 HCV/HIV CO-INFECTED PATIENTS: RESULTS OF THE MASTER-EPOKA-A COHORT IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.1C14) Torti C.1, Lapadula G.1, Casari S.1, Puoti M.1, Quiros-Roldan E.1, Bella D.1, Pastore G.2, Ladisa N.2, Minoli L.3, Sotgiu G.3, Mazzotta F.4, Lo Caputo S.4, Bonora S.5, Filice G.3, Carosi G.1 Higher risk of hepatotoxicity and different pattern of risk factors appeared in N compared to E patients. Single or multiple PI-based regimens were not associated with risk of hepatotoxicity either in N or E groups. A cautious approach and strict monitoring should be applied in HIV/HCV E patients with a previous hepatotoxicity, higher baseline ALT and prescribed NNRTI-containing regimens, who have an high risk of liver toxicity. |
| TuPe1.1C15 | STRATIFICATION OF RISK FOR MORTALITY BY BASELINE CD4 CELL COUNTS IN HEPATITIS C POSITIVE AND NEGATIVE INDIVIDUALS INITIATING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.1C15) Moore D., Braitstein P., Yip B., Montaner J., Hogg R. Baseline CD4 strata which are associated with increased non-accidental mortality appear to be similar for HCV negative and HCV positive receiving HAART, suggesting no benefit to earlier treatment of HCV positive individuals. |
| TuPe1.1C16 | SAFETY OF ABACAVIR (ABC)+LAMIVUDINE (3TC)-BASED HAART IN ART-NAÏVE HIV-INFECTED SUBJECTS WITH AND WITHOUT HEPATITIS B (HBV) AND/OR HEPATITIS C (HCV) CO-INFECTION IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.1C16) Zhao H., Hernandez J., Cutrell A., Givens N., Wakeford J., Scott T. In subjects treated with ABC+3TC based HAART, there was no significant difference in the incidence and/or type of AEs, grade 2-4 AEs or treatment emergent AEs, regardless of whether subjects were HBV and/or HCV co-infected or not. In addition, the incidence of specific adverse events in co-infected subjects did not differ between subjects taking ABC QD and those taking ABC BID. |
| TuPe1.1C17 | HEPATOCELLULAR CARCINOMA IN 40 HIV/HCV-COINFECTED VERSUS 50 HCV-MONOINFECTED PATIENTS. NORTH AMERICAN HCC IN HIV STUDY GROUP IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.1C17) Bräu N.1, Xiao P.2, Naqvi Z.3, Taylor L.E.4, Sulkowski M.S.5, Sherman M.6, Trikha A.1, Rigsby M.O.7, Martyn C.3, Dieterich D.T.8, Wright T.L.9, Brown S.T.1, Bini E.J.10 HIV/HCV-coinfected patients develop HCC at a younger age than HCV-monoinfected patients due to a shorter interval from HCV infection to HCC. In contrast to the European study, we did not find a difference in survival between HIV/HCV and HCV patients. |
| TuPe1.1C18 | EFFECT OF HIV CO-INFECTION ON SPONTANEOUS CLEARANCE OF HEPATITIS C VIRUS (HCV) IN THE DOWNTOWN EASTSIDE OF VANCOUVER IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.1C18) Grebely J.1, Conway B.1, Raffa J.2, Lai C.3, Krajden M.4, Kerr T.3, Wood E.3, Tyndall M.3 In this large community cohort, the prevalence of HCV and HIV/HCV co-infection were high at 63.5% and 18.5%, respectively. Co-infection with HIV and male gender decreases the likelihood of spontaneous clearance of HCV, while the presence of previous co-infection with HBV increases its likelihood. |
| TuPe1.1C19 | IMPACT OF SAFETY EVENTS ON SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PATIENTS WITH HIV-HCV CO-INFECTION ENROLLED IN THE AIDS PEGASYS RIBAVIRIN INTERNATIONAL CO-INFECTION TRIAL (APRICOT) IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.1C19) Sulkowski M.1, Pérez-Guzmán E.2, Moreno S.3, Marinos G.4, Dieterich D.T.5, Clumeck N.6, Opravil M.7 If AEs can be prevented or treated without the need for premature withdrawal, it may be possible to improve SVR rates. |
| TuPe1.1C20 | EFFECT OF HIV INFECTION ON LIVER ENZYMES OF HCV INFECTED PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.1C20) Langohr K., Sanvisens A., Santesmases J., Tor J., Rey-Joly C., Muga R. In individuals with chronic hepatitis C, HIV infection modifies the predictors of liver enzyme elevations. |
| TuPe1.1C21 | HISTOLOGICAL RESPONSE TO PEGINTERFERON α-2A (40KD) (PEGASYS®) PLUS RIBAVIRIN (COPEGUS®) IN HIV-HCV CO-INFECTED PATIENTS WITH BRIDGING FIBROSIS OR CIRRHOSIS IN THE AIDS PEGASYS RIBAVIRIN INTERNATIONAL CO-INFECTION TRIAL (APRICOT) IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.1C21) Lissen E.1, Clumeck N.2, Sola R.3, Mendes-Correa M.4, Montaner J.5, Nelson M.6, Sette Jr. H.7, Buggisch P.8, Main J.9, DePamphilis J.10, Dieterich D.T.11 Consistent with the overall population, HR was greatest in patients with bridging fibrosis/cirrhosis who received PEGASYS® plus COPEGUS®. Thus, even in patients with advanced liver disease, fibrosis and HAI inflammation scores can be improved with PEGASYS® plus COPEGUS®. |
| TuPe1.1C22 | HEPATOTOXICITY OF LOPINAVIR/RITONAVIR (LPV/R) BASED REGIMENS IN PATIENTS ATTENDING A HIV/HEPATITIS C/B CO-INFECTION CLINIC IN MIAMI IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.1C22) Moreno J., Zambrano J., Jayaweera D. In this cohort of patients infected with HCV, HBV or both, no hepatotoxicity was seen, irrespective of the HAART regimen used. There was no difference in hepatotoxicity. |
| TuPe1.1C23 | EFFICACY OF PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) PLUS RIBAVIRIN (COPEGUS®) IN PATIENTS WITH HCV GENOTYPE 4 INFECTION IN THE AIDS PEGASYS® RIBAVIRIN INTERNATIONAL CO-INFECTION TRIAL (APRICOT) IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.1C23) Soriano V.1, Mendes-Correa M.C.2, Gonçales Jr. F.L.3, Torriani F.J.4, Dieterich D.T.5, Cahn P.6, Findor J.A.7, Cassetti I.8, Sette Jr. H.9 Although the number of patients in APRICOT with genotype 4 was small, a 38% SVR rate in genotype 4 patients reflects the overall virological response rates in APRICOT (40%) for patients treated with PEGASYS®/COPEGUS®. This 38% SVR rate in genotype 4 patients treated with PEGASYS®/COPEGUS® is higher than that achieved in patients treated with genotype 1 infection. |
| TuPe1.1C24 | RISK FACTORS FOR DECOMPENSATED CIRRHOSIS AND ASSOCIATED MORBIDITY AND MORTALITY IN I.CO.N.A. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.1C24) Cicconi P.1, Puoti M.2, Cozzi Lepri A.3, Cosco L.4, Morsica G.5, Santantonio T.6, Ancarani F.7, Cargnel A.8, d'Arminio Monforte A.1 DC incidence in I.Co.N.A. is constant over calendar year and is affected by IDU and age. HAART doesn't influence DC incidence. DC-patients spend more time in hospital but the length of each stay is comparable to non-cirrhotics. DC-patients have an 8.5-fold increase in the risk of death and their survival is very poor. |
| TuPe1.1C25 | EFFECT OF RITONAVIR-BOOSTED ATAZANAVIR (ATV/R) IN EXPERIENCED HIV-INFECTED PATIENTS REGARDING CHRONIC HEPATITIS B/C STATUS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.1C25) Perez-Elias M.J.1, Gatell J.M.2, Flores J.3, Santos J.4, Vera F.J.5, Clotet B.6, Moreno A.1, Vendrell B.7, Perez-Molina J.A.7, Alvarez C.7, Ledesma E.8, Serrano O.7 In this relatively large cohort, ATV/r-containing HAART in co-infected patients was not associated with worsening liver function tests (including transaminases and bilirubin) vs non-co-infected patients. Virologic failure was uncommon in both groups. Therefore, ATV/r was a generally safe and well tolerated treatment option in patients with HBV and/or HCV co-infection. |
| TuPe1.1C26 | DIFFERENTIAL INFLUENCE OF THE DIFFERENT HEPATITIS VIRUSES ON QUALITY OF LIFE (QOL) IN HIV INFECTED INDIVIDUALS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.1C26) Tillmann H.L.1, Kaiser T.1, Heiken H.2, Schmidt R.E.2, Stoll M.2, Manns M.P.2 While HBV seems to play no role concerning QOL in HIV-infected patients, the falvi-viruses HCV and GBV-C differentially influence QoL. Thus maintenance of GBV-C viremia in HIV-infected patients may be beneficial for improved QoOL. |
| TuPe1.1C27 | INFLUENCE OF HTLV-2 INFECTION ON HEPATITIS C VIRUS REPLICATION IN HIV-POSITIVE PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.1C27) Toro C., Bassani S., Ríos P., Jiménez V., Camino N., Soriano V. Although HTLV-2 infection is frequently found in coinfection with HIV and HCV, our data suggest that it will not influence the rate of natural clearance of HCV in this population. HIV rather than HTLV-2 is the main cause for the lower HCV spontaneous clearance and higher HCV-RNA level noticed in patients with triple HCV, HTLV-2 and HIV infection. |
| TuPe1.1C28 | HCV CO-INFECTION AMONG HIV-1 INFECTED PERSONS IN AN ARGENTINEAN PROVINCE: DISTRIBUTION OF HCV-GENOTYPE IN DIFFERENT RISK GROUPS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.1C28) Fay F.1, Campodonico M.1, Benetti S.1, Lejona S.1, Bortolozzi R.2, Gambino P.3, Amin M.4, Fay O.5 Observed global HCV co-infection prevalence among HIV-1 infected people in Santa Fe was 48% (95% CI: [41.7;54.3]). HCV replication was observed in 87.5% (95% CI: [81.6;93.4]) of co-infected patients without significant difference among risk groups (p>0.05). Genotype 1 was prevalent (72% [63.4;80.6]) despite risk group (p>0.05). Anti-HCV(-) with HCV-RNA(+) observed in 15% of co-infected patients emphasizes the importance of using PCR as HCV screening tool in HIV-1 infected patients. |
| TuPe1.1C29 | THE RELATIVE ROLE OF HCV-COINFECTION, ADHERENCE TO ANTIRETROVIRALS AND PLASMA DRUG LEVELS ON THE INCIDENCE OF ALT ELEVATION DURING HAART IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.1C29) Ammassari A.1, Cozzi-lepri A.2, Trotta M.P.3, Bonora S.4, Marconi P.3, Repetto D.5, Nasta P.6, Di Perri G.4, d'Arminio Monforte A.5, Antinori A.3 HCV co-infection and longer duration of ART, rather than use of specific drugs, seem to be associated with an increased risk of ALT elevation. These associations could not be explained by differences in adherence behaviour or antiretroviral levels. |
| TuPe1.1C30 | ANTIRETROVIRAL THERAPY AND THE DETECTABILITY OF HCV RNA IN A POPULATION-BASED COHORT OF HIV-INFECTED ADULTS INITIATING HIV TREATMENT IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.1C30) Braitstein P.1, Krajden M.2, Sherlock C.3, Yip B.4, Galli R.4, Harrigan P.R.3, Schechter M.T.3, Montaner J.S.G.4, Hogg R.S.4 There is a very high prevalence of HCV-positive Ab (51%) in this population-based cohort of HIV-infected individuals, and a high prevalence of Ab+/RNA- discordance (25%). Our study suggests some individuals with undetectable HCV RNA at baseline may develop detectable HCV RNA post-ART initiation. |
| TuPe1.1C31 | OCCULT HEPATITIS B VIRUS INFECTION IN A COHORT OF HIV INFECTED PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.1C31) Marino N.1, Lo Caputo S.1, Pierotti P.1, Blé C.1, Riccardi M.P.2, Trezzi M.2, Toti M.2, De Gennaro M.3, Scasso A.3, Vivarelli A.4, Dionisio D.4, Mazzotta F.1 Occult HBV infection is frequent in HIV-infected patients; HBV-DNA was positive in 14,3% of anti-HBc + patients, but longitudinal evaluation of HBV-DNA is necessary for correct diagnosis of occult HBV infection. |
| TuPe1.1C32 | REDUCTION IN LIVER-RELATED HOSPITAL ADMISSIONS AND DEATHS IN HIV+ PATIENTS SINCE YEAR 2001 IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.1C32) Sanchez-Somolinos M.1, Martin-Carbonero L.1, Valencia M.E.1, Samaniego J.1, Romero M.1, Nuñez M.J.2, González-Lahoz J.1, Soriano V.1 Overall, liver-related complications currently are the 2nd cause of hospital admission for HIV+ patients, following bacterial respiratory infections and preceding tuberculosis. Chronic hepatitis C is by far involved in most cases of CVLD in our series. Liver-related deaths increased from 9% (5/54) in 1996 to 53% (9/17) in 2001, but steadily declined since then, being of 23% (4/17) in 2004. The rate of liver-related hospital admissions and deaths among HIV+ patients peaked in year 2001, and have steadily declined since then. |
| TuPe1.1C33 | HIV/HCV AND HIV/HBV CO-INFECTIONS PREVALENCE IN A COHORT OF ROMANIAN ADULT PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.1C33) Benea E., Popescu G.-A., Popescu C., Badea G., Ivan M., Gavriliu L.C. The prevalence of HIV/HCV co-infection is very low compared with European Western countries, associated with the low level of intravenous drug HIV-acquired infection in Romania. The situation of HIV/HBV is opposite: high level, similar with other Southern European countries. The raised level of HIV/HBV co-infection in patients born between 1981-1990 could be correlated with some gaps in infection-control practices in the last years of communist period in Romania (1985-1990). |
| TuPe1.1C34 | SEROPREVALENCE OF HEPATITIS B VIRUS (HBV) AND HEPATITIS C VIRUS (HCV) INFECTIONS AMONG HIV-INFECTED PATIENTS ATTENDING THE ANTIRETROVIRAL CLINIC AT THE JOS UNIVERSITY TEACHING HOSPITAL (JUTH), JOS. NIGERIA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.1C34) Agbaji O.1, Badung B.1, Idoko J.1, Kanki P.2 The prevalence of HBV and HCV were high among our HIV-infected patients. This has implications in a resource constrained setting like ours, where the available antiretroviral drugs with efficacy against HBV and HCV may either not be available or where available may not be affordable. Since HBV and HCV are important causes of morbidity and mortality in HIV-infected persons, screening for these chronic viral hepatitis infections should be made mandatory. Vaccination against HBV in those who are non-immune is also essential to prevent infection and subsequent complications. |
| TuPe1.1C35 | DIFFERENCES IN NEUROPSYCHOLOGICAL FUNCTIONING BETWEEN HIV+ AND HIV+/HCV+ INFECTED PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.1C35) Muñoz-Moreno J.A.1, Fumaz C.R.1, Prats A.1, Ferrer M.J.1, Negredo E.1, Moltó J.1, López-Blázquez R.2, Gómez G.2, Garolera M.3, Clotet B.1 Differences in NF are found between HIV-monoinfected and HIV/HCV-coinfected patients. Coinfected subjects show significant impairment in motor performance, verbal fluency and executive functions. |
| TuPe1.1C36 | PREVALENCE OF SEROLOGIC MARKERS OF HEPATITIS B AND C VIRUSES AMONG HIV INFECTED PATIENTS IN IPEC/FIOCRUZ – RIO DE JANEIRO, BRAZIL IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.1C36) Silva A.C.M., Moreira R.I., Soares J.C., Grinsztejn B., d'Almeida R.G., Scarpellini B., Georg I., Pilotto J.H. Our data shows a large proportion of patients susceptible to hepatitis B infection. In Brazil, vaccination programs are more focused on childhood and access of adults to hepatitis B is still limited. Due to the impact of HBV/HCV in HIV-infection morbidity and mortality, all HIV infected individuals must be tested for HBV/HCV for appropriate management and treatment. |
| TuPe1.1C37 | EPIDEMIOLOGICAL BEHAVIOUR OF HIV, HEPATIIS B VIRUS (HBV) AND HEPATITIS C VIRUS (HCV) CO-INFECTION IN A SAMPLE OF THE VENEZUELAN POPULATION IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.1C37) Mantilla P.1, Delgado D.1, Roldan Y.2, Monzón A.1, Hernandez G.1, Quintero V.1, Paez X.2 Prevalency of HIV-HBV is higher than reported by literature, but HCV is lower because the use of endovenous drugs is not frequent in Venezuela. Clinical Behaviour and epidemiological data of HIV-HBV and HIV-HCV co-infection are similar to the documented in other locations. Patients with Anticore+ must be evaluated for reactivation or lack of immunity of infection. Genotype 1 is frequent in HIV-HCV. 70% of the patients require vaccination to prevent HBV. |
| TuPe1.1C38 | HAART-ASSOCIATED HEPATOTOXICITY IN HIV/HCV CO-INFECTED PATIENTS WITH ADVANCED CHRONIC LIVER DISEASE OR CIRRHOSIS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.1C38) Aranzabal L., Casado J., Quereda C., Moya J., Moreno A., Antela A., Marín A., Perez-Elías M.J., Moreno S. HAART-associated hepatotoxicity is closely correlated with HCV-related liver histological damage. In patients with advanced CLD, nearly one third could develop toxicity. |
| TuPe1.1C39 | RISK OF LIVER TOXICITY IN HCV/HIV COINFECTED PATIENTS WITH ADVANCED CHRONIC LIVER DISEASE OR CIRRHOSIS RECEIVING NEVIRAPINE, EFAVIRENZ OR LOPINAVIR/R IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.1C39) Casado J., Aranzabal L., Moya J., Quereda C., Moreno A., Antela A., Marín A., Perez Elías M.J., Moreno S. The risk of hepatotoxicity is similar in HCV/HIV coinfected patients with mild-moderate fibrosis receiving NNRTIs or lopinavir/r. Plasma trough levels of NNRTIs are not correlated with liver toxicity. |
| TuPe1.1C40 | ANALYSIS OF DEATHS OF HIV INFECTED PATIENTS IN LODZ REGION IN POLAND IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.1C40) Jablonowska E., Malolepsza E., Kuydowicz J. 1. AIDS is still the leading cause of death in HIV+ patients in Lodz district. 2. The emerging cause of death in HIV+ patients is end stage liver disease as the sequel of HBV/HCV infection. 3. High frequency of HIV/HCV coinfections in our patients prognoses growing rate of liver disease as the cause of death. |
| TuPe1.1C41 | RECOMBINANT HEPATITIS B VACCINATION IN PATIENTS WITH HIV/AIDS: IMMUNE RESPONSES AND EFFECTIVENESS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.1C41) Sud A., Kumari N., Arora S., Singh S., Chawla Y. Antibody response to HBV vaccination is sub-optimal in HIV-infected patients. The titers are lowest in patients with CD4 counts <200/mm³. Basal naïve cell counts, though lower in patients with CD4<200/mm³, increase after vaccination. The increase in memory cells occurs later in patients with CD4 count <200/mm³ |
| TuPe1.1C42 | LIVER BIOPSY (LB) FINDINGS IN HIV INFECTED PATIENTS (HIV+P) WITH CHRONIC C HEPATITIS (CHC) AND PERSISTENTLY NORMAL ALANINE TRANSAMINASE (PNALT) IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.1C42) Sánchez-Conde M., Alvarez F., Berenguer J., Miralles P., Alvarez E., Cosin J., Lopez J.C., Ramirez M., Gutierrez I., Bellon J.M. In HIV infected patients (HIV+P) with chronic Hepatitis C (CHC), persistently normal alanine transaminase (PNALT) correlates with lower fibrosis scores than elevated ALT (EALT). The association found between HCV genotype, duration of HAART and PNALT in this population group merits further study. Although we did not found advanced stages of fibrosis (F3 – F4) in patients with PNALT, approximately one quarter of these patients had a significant stage of fibrosis (F2). This finding suggests that LB may be indicated in HIV+P with CHC and PNALT. |
| TuPe1.2C HIV and STD interactions |
|
| TuPe1.2C01 | A STUDY OF PREVALENCE OF STDS FROM A RURAL VILLAGE IN GUJRAT,INDIA AMONG THE REPRODUCTIVE AGE GROUP (15-49 YRS) SUBJECTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.2C01) Bhalla S.1, Lalchandani K.2, Singh s.3, Somasundaram c.2, Bhalla V.1 Information about transmission of HIV/STDs needs to be targeted. Provision of syndromic management of STD and strengthing of HIV counseling. More and more IEC activities to be taken in rural areas, with the help of audio visual displays and drama or role pay. Health education about maintenance of personal hygienean encourage National and International reproductive health, family planning and AIDS programmes as well as donor agencies to include condom provision and distributin in their programming and funding priorities. |
| TuPe1.2C02 | RISK BEHAVIOUR AMONG BLOOD DONORS WHO GIVE BLOOD IN ORDER TO BE TESTED FOR HIV IN SHIRAZ BLOOD TRANSFUSION IN 2003 IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.2C02) Kasraian L., Torabjahromi, Farahangiz In this survey 14.8[%] of people donate blood for HIV check up and this can be dangerous for blood safety. The most risk factor that reported was sexual contact For safe blood supply we have to educate people in order to not donate blood for health check up and discussing population about residual risk of HIV transmission through blood and importance of blood donor for blood safety. |
| TuPe1.2C03 | THE OCCURRENCE OF SYPHILIS DOES NOT APPEAR TO INTERFERE WITH THE IMMUNOLOGICAL AND VIROLOGICAL COURSE OF AN UNDERLYING HIV INFECTION: A PROSPECTIVE, OBSERVATIONAL SURVEY IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.2C03) Manfredi R., Sabbatani S., Pocaterra D., Calza L., Chiodo F. Although bidirectional interactions between syphilis and HIV were not investigated in-depth on both immunological and virological basis, animal models and ex-vivo studies show that the HIV-associated quantitative-functional impairment of cell-mediate immunity may modify the course of syphilis. Concurrently,altered migration and clearance of immune system cells,an abnormal cytokine network,and a tendency towards apopotosis of lymphoid cells,were demonstrated during the different stages of syphilis. However,it's difficult to hypothesize that a non-opportunistic disease like syphilis may significantly influence HIV disease course, especially during HAART. While we share concerns about the increasing STD among HIV-infected patients, differently from recent literature reports (AIDS. 2004 Oct 21;18(15):2075-9.), in our experience syphilis does not seem to alter the laboratory course of HIV infection. |
| TuPe1.2C04 | USE OF THE STARHS ASSAY TO IDENTIFY RECENTLY ACQUIRED HIV INFECTIONS IN MEN WITH EARLY SYPHILIS IN LOS ANGELES COUNTY IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.2C04) Taylor M.1, Hawkins K., Gonzalez A.3, Buchacz K.4, Aynalem G., Smith L., Klausner J.5, Holmberg S.4, Kerndt P. Syphilis epidemics in MSM may be contributing to HIV incidence rates in this population. STARHS can be applied as a surveillance tool to assess relationships, but further studies are necessary to determine its value. |
| TuPe1.2C05 | SYPHILIS TREATMENT AND HIV INFECTION IN A POPULATION-BASED STUDY OF PERSONS AT HIGH-RISK FOR STD/HIV INFECTION IN LIMA, PERU IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.2C05) Long C.1, Klausner J.1, Leon S.2, Jones F.3, Cuadros J.2, Giron M.2, Pajuelo J.2, Caceres C.2, Coates T.4, NIMH Collaborative HIV/STD Prevention Trial Group 5 Syphilis is common in this population and associated with HIV infection. While cure rates were high, re-infection was common. Those with initial RPR titers of < 1:8 required additional treatment more frequently and still may have been less likely cured after one year. HIV status did not affect syphilis cure rates. Improved syphilis treatment can aid in HIV prevention. |
| TuPe1.2C06 | EVALUATION OF CEREBROSPINAL FLUID IN HIV AND NON-HIV PATIENTS WITH ASYMPTOMATIC LATE SYPHILIS OF LOW VDRL TITER IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.2C06) Park W.B.1, Lee C.S.1, Park K.W.1, Bang J.W.1, Kim H.B.1, Kang M.-W.2, Oh M.-d.1, Choe K.W.1 In the patients with asymptomatic late syphilis, a low VDRL titer cannot rule out neurosyphilis, especially in HIV patients. |
| TuPe1.2C07 | PREVALENCE OF HIV SUBTYPES, HTLV, HBV AND HCV AMONG IMMIGRANT SEX WORKERS IN MADRID, SPAIN IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.2C07) Gutierrez M., Alvarez A., Tajada P., Baquero M., Soriano V., Amor A., Holguin A. A relatively high prevalence of HIV-1 infection was found among immigrant sex workers in Madrid, particularly among those coming from Liberia and Ecuador. Epidemiological implications of the presence and spread of HIV-1 non-B subtypes and recombinant viruses in this collective needs to be further assessed. |
| TuPe1.2C08 | CHANGES IN NATURAL COURSE OF SYPHILIS IN HIV INFECTION IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.2C08) Ceccarelli G., d'Ettorre G., Carnevalini M., D'Agostino C., Dell'Isola S., Lichtner M., Massetti A.P., Mastroianni C.M., Vullo V. Our data suggest that during the course of HIV infection, the natural course of syphilis is modified. We observed simultaneous primary, secondary and neuro-syphilis. |
| TuPe1.2C09 | CEREBROSPINAL FLUID HIV RNA LEVELS IN PATIENTS WITH NEUROSYPHILIS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.2C09) de Almeida S.1, Durelle J.1, Lazzaretto D.1, Beck J.1, Smith D.2, McCutchan A.1, Letendre S.1, Grant I.1, Ellis R.1 Neurosyphilis may amplify intrathecal HIV replication, possibly through immune activation. It is known that elevated CSF RNA levels correlate with cognitive impairment, neurosyphilis may cause increased CNS manifestations of HIV. |
| TuPe1.2C10 | SERO-PREVALENCE OF HIV AMONG SEX WORKERS IN JOS, NIGERIA. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.2C10) Egah D. This study records a high prevalence of HIV. In a low socioeconomic, literacy and developing health system in a country like ours, limited health services are hardly accessible. Also, sex work is not legalized in our country therefore the sex workers suffer from sever stigmatization. This makes it very difficult for them competing for the scarce health services available for the general population. In the light of the above and the fact that the HIV vaccine is not yet available, a special HIV intervention programmes to target this high-risk group and reservoir of HIV infection is critical in the control/prevention of HIV in the larger population. |
| TuPe1.2C11 | CIN INCIDENCE AFTER LEEP CONIZATION BETWEEN HIV-INFECTED AND HIV-NON-INFECTED WOMEN IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.2C11) Lima M.I.M.1, Melo V.2, Tafuri C.P.1, Araújo A.C.L.1 CIN recurrence rate is higher in seropositive women. Factors associated to recurrence were HIV-infection, glandular involvement and positive margins in cone biopsies. T CD4+ cells count below 200 cells/mm was a risk factor to CIN recurrence in HIV-infected women. |
| TuPe1.2C12 | INCREASED ACTIVITY OF MATRIX METALLOPROTEINASES IN THE CEREBROSPINAL FLUID OF PATIENTS WITH HIV/SYPHILIS COINFECTION. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.2C12) D'Agostino C., Di Campli N.F., Miccoli G.A., Dell'Isola S., d'Ettorre G., Mastroianni C.M., Vullo V. These findings could suggest that syphilis infection during HIV infection could contribute to brain barrier injury. |
| TuPe1.2C13 | DRUG USE FUELS HIV AND STDS IN A SEMI-RURAL COMMUNITY IN INDIA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.2C13) Menezes L.1, Raja T.2, Tash K.3, Naik E.1, Nadler J.1, Sinnott J.1 Surprisingly, drug use was strongly associated with STDs and HIV in this semi-rural community. Additionally, individuals with STDs were more likely to have advanced HIV. Drug use in these marginalized communities poses a risk for the acquisition and transmission of HIV and other STDs. Whether these factors are synergistic or additive is unclear. However, drug use is contributing to the HIV epidemic in India. |
| TuPe1.2C14 | THE IMPACT OF ALCOHOL CONSUMPTION ON THE INCIDENCE OF STIS AMONG HIV POSITIVE WOMEN. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.2C14) Rusch M.1, Shannon K.2, Ishida T.2, Lai C.2, Tyndall M.1 The risk of STD infection is strongly related to alcohol consumption among HIV positive individuals. This does not appear to be the case for HIV negative individuals in whom non-injection drug use such as crack cocaine and crystal methamphetamine are the primary risk factor. |
| TuPe1.2C15 | GYNECOLOGICAL SELF-REPORTED SYMPTOMS IN A HIV INFECTED WOMEN COHORT FOLLOWED AT IPEC/FIOCRUZ, RIO DE JANEIRO - BRAZIL IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.2C15) Andrade A., Pires E.S., Friedman R., Derrico M., Lourenço M., Faria D.L., Araujo D.C., Cunha C.M., Moreira R., Grinsztejn B. Gynecological self-reported symptoms were highly prevalent among these women in spite of the continuous gynecologic care provided to them. |
| TuPe1.2C16 | SURVEY OF NEUROSYPHILIS (NSI) PREVALENCE, DIAGNOSED BY CEREBROSPINAL FLUID (CSF), IN HIV-POSITIVE PATIENTS WITH MOSTLY SECONDARY INFECTIOUS SYPHILIS (SI) AND RECOMMENDED CSF-REPUNCTURE AFTER TREATMENT FOR THERAPY CONTROL IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.2C16) Koppermann M., Grabbe S., Esser S. 15 % of the HIV-positive patients with infectious SI had signs of early NSI. No treatment failure was observed in repuncture. This survey shows increased risk of NSI in HIV-Infected patients but obviously no treatment failure after sufficient therapy. |
| TuPe1.3C HPV |
|
| TuPe1.3C01 | DETECTION AND CORRELATION WITH PRO-INFLAMMATORY CYTOKINES EXPRESSION IN THE UTERINE CERVIX FROM HIV/HPV INFECTED WOMEN IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.3C01) Nicol A.1, Nuovo J.2, Y W.2, Gage J.3, Grinsztejn B.4, Tristão A.5, Russomano F.5, Perez M.4, Fernandes A.T.1, Martínez-Maza O.3, Bonecini-Almeida M.G.1 This suggests that viral-related suppression of SOCS/SSI-1-3 expression may be a factor in the marked local enhancement of TNF-α and IL-6 production which, in turn, may help facilitate viral spread. |
| TuPe1.3C02 | DETECTION OF HUMAN PAPILLOMAVIRUS IN PERIPHERAL BLOOD CELLS OF HIV-1-INFECTED PREGNANT WOMEN. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.3C02) Santos G.1, Mota G.1, Diaz R.1, Castelo A.1, Souza I.2 There was a correlation between high HPV genital VL and low CD4 T counts with the presence of HPV infection in the blood stream. The role of HPV viremia is controversial and warrants further investigation to determine its relationship with genital infection and whether there is a correlation with development of malignancies in HIV-infected individuals. |
| TuPe1.3C03 | CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) TREATMENT IN HIV-POSITIVE WOMEN: A RETROSPECTIVE STUDY. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.3C03) Shah S.1, Montgomery H.2, Smith C.1, Evans H.2, Sabin C.1, Johnson M.2 Our results indicate that the descrepancy between cytology and histology is high in HIV-positive women, highlighting the need for HPV testing in this group. Additionally, there is often incomplete excision of resection margins, consequently persistence of abnormalities require further treatment. Further work showing a beneficial effect of HAART on reducing HPV DNA load and causing regression of CIN could prevent these women undergoing repeated treatments. |
| TuPe1.3C04 | HPV PREVALENCE IN HIV-INFECTED WOMEN IN A MULTICENTER STUDY IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.3C04) Melo V.1, Araújo A.C.L.2, Corrêa C.M.1, Campos R.3, França A.F.4, Oliveira H.C.5, Faria I.M.1, Castillo D.M.6, Nogueira C.P.6, Faria L.M.1, Faria F.M.1, Zimmermmann J.B.7 HPV prevalence in HIV-infected women is high. Multiple associations are very frequent with predominance of high risk types. |
| TuPe1.3C05 | HIGH FREQUENCY OF SQUAMOUS INTRAEPITHELIAL LESIONS AMONG HIV+ MSM EVALUATED AT THE ANAL DYSPLASIA CLINIC (ADC) IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.3C05) Guillemi S.A.1, Hogg R.1, Ruth J.1, Taylor R.2, Montaner J.S.1 We observed a high incidence of abnormal biopsy results (86%) in HIV+ MSM . There was a weak correlation between PAP and anal biopsy results. Baseline characteristics failed to predict the results of anal biopsies. These findings were not affected by HAART use. |
| TuPe1.3C06 | ONCOGENIC HUMAN PAPILLOMAVIRUS HPV-18 E2 PROTEIN SHARES A TETRAPEPTIDE LQGL WITH C-ERBB2, AND HPV-33 E2 PROTEIN IS HOMOLOGOUS TO HEREGULIN (HRG)-α IN 3 DIMENSIONS. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.3C06) Tran M.K.G.1, Caprani A.2, Richert A.3, Maurisson G.4 Oncogenic HPV-33 E2 early protein is homologous to the oncogene HRG-a which binds to c-ErbB3 and c-ErbB4. HPV-18 seems to mimick the c-ErbB2 extra-cellular region LQGL. Monoclonal antibodies against EGFR and c-ErbB2 may have indirect efficiency against HPV infection. HPV vaccine should include these E2 epitopes. |
| TuPe1.3C07 | INCIDENCE OF CERVICAL INTRAEPITHELIAL NEOPLASIA IN HIV POSITIVE WOMEN AT HAART ERA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.3C07) Kreitchmann R., Mello K., Preussler G., Correa M.D.G. HAART significantly reduces the incidence of cervical intraepithelial lesions. Nevertheless, HIV infected women do have a high rate of CIN in cervical pap smears and need to participate in cervical cancer screening programs as part of their standard of care. |
| TuPe1.4C Other co-infections |
|
| TuPe1.4C01 | EPSTEIN-BARR VIRUS-ASSOCIATED SMOOTH-MUSCLE TUMOR IN ACQUIRED IMMUNODEFICIENCY SYNDROME IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.4C01) Suankratay C.1, Shuangshoti S.2, Mutirangura A.3, Wilde H.4 SMTs in AIDS patients typically arise in multiple and very unusual sites which are not observed in immunocompetent individuals. Our series also suggests association between EBV and the SMT. |
| TuPe1.4C02 | DAILY VALACYCLOVIR IS SAFE AND EFFECTIVE IN REDUCING RECURRENT HSV-1, HSV-2 AND VZV IN HIV/AIDS PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.4C02) Greiger-Zanlungo P.1, Blick G.2, Dupree D.3, Gupta S.3, Garton T.2 Valacyclovir is equally safe and effective in reducing recurrent HSV-1, HSV-2 and VZV in both arms. Recurrences were mostly attributable to non campliance, while adverse events were mild, self-limiting and not responsabile for discontinuation of therapy. |
| TuPe1.4C03 | EXPERIMENTAL STUDY OF THE COMPLEX BI-DIRECTIONAL INTERACTIONS BETWEEN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) AND THE PROTOZOAN PARASITE LEISHMANIA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.4C03) Zhao C., Cantin R., Tremblay M.J. These findings help to unravel the molecular cellular mechanisms through which the two microorganisms interact, provide novel insight into the complex relationships between both human pathogens, and, most importantly, offer information that may be useful for the design of effective therapeutic strategies to control disease progression in persons dually infected with HIV-1 and Leishmania. |
| TuPe1.4C04 | MUCOCUTANEOUS MANIFESTATIONS OF HIV INFECTION IN A TERTIARY CARE HOSPITAL IN INDIA IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.4C04) Verma K., Tejasvi T., Mahesh R. Majority of our patients had manifestations of infectious etiology while some of the manifestations were coincidental associations unrelated to the stage of HIV infection. |
| TuPe1.4C05 | HHV-8-RELATED LIMPHOPROLIFERATIVE DISORDERS DURING HIV INFECTION: A MONOINSTITUTIONAL EXPERIENCE IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.4C05) Simonelli C., Tedeschi R., Gloghini A., Bortolin M.T., Spina M., Talamini R., Cinelli R., Vaccher E., De Paoli P., Carbone A., Tirelli U. MCD pts showed a significantly shorter OS and a significantly lower value of HHV-8 viraemia in comparison with Solid-HHV-8 L pts. Solid-HHV-8 L pts had a significantly shorter median OS and a lower HHV-8 viraemia in comparison with PEL pts. When OS was stratified according to HHV-8 viraemia, pts with value >40000 cp/ml had a significantly shorter OS. The multivariate analysis identified only histology as a significant adverse prognostic factor. Supported by ISS grants. |
| TuPe1.4C07 | GB VIRUS C INFECTION IS ASSOCIATED WITH IMPROVED IN VITRO SURVIVAL OF PBMC FROM HIV INFECTED PATIENTS IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd:(abstract no. TuPe1.4C07) |